Inhibition of Melanoma Growth by Subcutaneous Administration of hTERTC27 Viral Cocktail in C57BL/6 Mice

Abstract

Background

hTERTC27 is a 27 kDa C-terminal polypeptide of human telomerase reverse transcriptase that has previously been shown to reduce tumorigenicity of HeLa cells and suppress growth of xenografted glioblastoma in nude mice. Although ectopic expression of hTERTC27 upregulated genes that are involved in apoptosis, cell cycle, and immune response, the mechanism for hTERTC27-induced tumor suppression has not been completely elucidated. Since hTERT was identified as a universal tumor-associated antigen, we hypothesize that hTERTC27 inhibits tumor growth in vivo through activation of anti-tumor immune response.

Methodology/Principal Finding

Immunocopetent C57BL/6 mice were used for mouse B16 melanoma model. Mice bearing B16 melanoma were administered rAAV-/rAdv viral cocktail expressing hTERTC27, and tumor growth was monitored after viral cocktail treatment. Blood and splenocytes were used to determine the level of cytokines and the activity of immune cells, respectively. B16 tumor growth was significantly inhibited by subcutaneous administration of a single dose of 1.5×1011 vg rAAV-hTERTC27 and 2.5×109 pfu rAdv-hTERTC27 viral cocktail (rAAV-/rAdv-hTERTC27). The population and cytotoxicity of NK cells in the mice were significantly augmented by rAAV-/rAdv-hTERTC27 treatment, and selective depletion of the NK cell population in mice by intraperitoneal injection of anti-GM1 antibody abrogated the growth suppression of melanoma induced by rAAV-/rAdv-hTERTC27 administration.

Conclusion

Activation of NK cells by administration of rAAV-/rAdv-hTERTC27 is critical for growth suppression of melanoma in mouse model.

About the Authors:

Longfei Huo

Current address: Department of Molecular & Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

Affiliation: Open Laboratory of Chemical Biology of the Institute of Molecular Technology, Department of Chemistry, The University of Hong Kong, Pokfulam, Hong Kong, China

Hong Yao

Affiliations Open Laboratory of Chemical Biology of the Institute of Molecular Technology, Department of Chemistry, The University of Hong Kong, Pokfulam, Hong Kong, China, Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China

Xicai Wang

Affiliation: Tumor Hospital of Yunnan Province, Tumor Institute of Yunnan Province, Cancer Research Department of Biomedical Engineering Research Centre, Kunming Medical College, Kunming, China

Gee Wan Wong

Affiliations Open Laboratory of Chemical Biology of the Institute of Molecular Technology, Department of Chemistry, The University of Hong Kong, Pokfulam, Hong Kong, China, Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, Hong Kong, China

Hsiang-fu Kung

Affiliation: Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, Hong Kong, China

Marie C. Lin

* E-mail: [email protected]

Affiliations Open Laboratory of Chemical Biology of the Institute of Molecular Technology, Department of Chemistry, The University of Hong Kong, Pokfulam, Hong Kong, China, Brain Tumor Center, Neurosurgery, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China

Introduction

The frequency of melanoma cases in Western countries has risen rapidly over the last years, and melanoma has become one of the most fatal cancers [1]. Local melanoma can be cured by wide surgical excision at its early stage [2], but metastatic melanomas are usually incurable [3]. Chemotherapy (e.g. dacarbazine) and cytokine adjuvant therapy (e.g. high-dose IFN-α2b and IL-2) are commonly used as a palliative systemic therapy in patients with advanced melanoma [4], [5], [6]. However, the non-specificity and significant side effects of these therapies greatly limit their effective use in patients [2], [7], [8], [9]. Biochemotherapy, a combination therapy of cytokine adjuvant with chemotherapeutic agents, has been shown to improve response rates but not overall survival. Moreover, biochemotherapy has been found to be associated with increased toxicity [10], [11]. Recently, several Phase II/III clinical trials are ongoing for the use of CTLA4 monoclonal antibodies as a new promising strategy for the treatment of metastatic melanoma [12]; however, significant autoimmune-related side effects have been increasingly observed [13], [14], [15]. Cancer vaccines, on the other hand, exhibit higher specificity and less toxicity, and their development has made rapid progress in recent decades [10], [16], [17], but the therapeutic efficacy has been very low with the reported overall objective response rate of only 3.3% [18].

Telomeres are specialized structures at the end of eukaryotic chromosomes that function to prevent chromosome end-joining and maintained by telomerase, a ribonucleoprotein complex that functions in elongating telomeres using reverse transcriptase and a specific RNA molecule in the complex. Telomere length loss occurs with cell division in somatic cells in which telomerase activity is absent and induces replicative senescence and cell proliferation inhibition when the length decreases to below a certain threshold [19]. In contrast, immortal cells like stem cells and cancer cells express high telomerase activity and show little loss of telomere length with cell division, and thus escape replicative senescence and proliferate indefinitely [20]. Telomerase reverse transcriptase (TERT), the catalytic peptide subunit of telomerase, is expressed in more than 85% of human tumor cells but rarely in normal cells, making it an ideal target for antigen-specific cancer immunotherapy [21], [22]. Indeed, studies have shown that TERT able to trigger antitumor cytotoxic T lymphocyte (CTL) responses, and immunization of mice with TERT stimulated TERT-specific CTL that can kill cancers of various origins [23], [24], [25].

hTERTC27 is an artificially derived 27 kD C-terminal polypeptides of human TERT [26]. Overexpression of hTERTC27 in HeLa cells caused excessive chromosome end joining events without affecting telomerase activity in TRAP assay [26]. Previously, we developed a novel cancer gene therapy using recombinant adeno-associated virus (rAAV) as delivery vector for hTERTC27 (i.e. rAAV-hTERTC27). In a glioblastoma xenograft mouse model, we observed that ectopic expression of hTERTC27 in tumor cells induced tumor regression and significantly prolonged survival of tumor-bearing mice. The action of hTERTC27 on tumors is mechanistically complex. For instance, transduction of tumor cells with rAAV-hTERTC27 induced cell apoptosis and inhibited tumor angiogenesis. Moreover, we observed an influx of ploymorphonuclear neutrophils into hTERTC27-treated tumor xenograft, and upregulation of gene expression involved in immune response [27], suggesting that the immune response might play a role in tumor regression.

Previously, it has been reported that administration of adeno-associated virus (rAAV) with adenovirus (rAdv) together can increase AAV transduction efficiency by >100 fold [28]. For example, the rAAV-BMP2-induced osteogenic activity was successfully enhanced by combination of rAAV-BMP2 with a low level of rAdv-BMP2 [29]. Similarly, a low level of rAdv-hTERTC27 greatly enhanced the expression of hTERTC27 transgene carried by rAAV, and rAAV-/rAdv-hTERTC27 viral cocktail potently inhibited xenografted glioblastoma growth [30].

In this study we tested the efficacy of the rAAV-/rAdv-hTERTC27 viral cocktail in treating melanoma and explored the possible involvement of immune response in cancer regressions mediated by rAAV-/rAdv-hTERTC27 treatment using an immunocompetent mouse model of melanoma. We found that a single dose administration of viral cocktail of hTERTC27 was sufficient to significantly inhibit the tumor growth of melanoma in C57BL/6 mice. The innate arm of immunity mediated by NK cells and adaptive immunity mediated by Th1 cytokines seemed to play an important role in this anti-tumor effect. The potential beneficial effects of supplementing rAAV-/rAdv-hTERTC27 gene therapy with other therapies for prevention and treatment of melanoma metastasis warrant further investigations.

Materials and Methods

Animals, cells, antibodies and reagents

Female C57BL/6N mice (6–8 weeks old) were purchased from the Charles River Laboratories (Wilmington, MA) and housed under aseptic conditions and cared for according to the guidelines issued by the University of Hong Kong's Laboratory Animal Unit. Mice were fed for three days before the experiments. All experimental protocols were approved by the Department of Health of the Government of HKSAR [permit number: (411) in DH/ORHI/8/2/3 Pt. 5] and the University of Hong Kong's Committee on the Use of Live Animals in Teaching and Research (approval ID: CULATR 1334–06).

Mouse melanoma B16-F1 (ATCC, CRL-6323) cells were cultured in DMEM supplemented with 10% heat inactivated FBS, 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen, Carlsbad, CA) at 37°C with 5% CO2. YAC-1 (ATCC, TIB-160) cells were maintained in RPMI-1640 medium supplemented with 10% heat inactivated FBS and antibiotics (100 U/ml penicillin & 100 µg/ml streptomycin).

CytoTox 96 Non-Radioactive Cytotoxicity Assay and CellTiter 96 Non-Radioactive Cell Proliferation Assay Kit were purchased from Promega (Promega, WI, USA). Mitomycin C, Lipopolysaccharides (LPS) from Escherichia coli O111:B4, Concanavalin A (ConA), and Histopaque®-1083 were obtained from Sigma (Sigma, MO, USA). Red blood cell lysis buffer, recombinant mouse IL-2, R-Phycoerythrin (R-PE)-conjugated rat anti-mouse CD4 monoclonal antibody (L3T4), Fluorescein Isothiocyanate (FITC)-conjugated rat anti-mouse CD8a monoclonal antibody (Ly-2), R-PE-conjugated rat anti-mouse CD49b/Pan NK monoclonal antibody (DX5), FITC-conjugated rat anti-mouse CD3 monoclonal antibody (17A2), FITC-conjugated rat anti-mouse CD19 monoclonal antibody (1D3) were all obtained from BD Biosciences (BD Bioscience Pharmingen).

Production of recombinant adenovirus (rAdv) and adeno-associated virus (rAAV)

Recombinant adenovirus-hTERTC27 (rAdv-hTERTC27) and recombinant adeno-assoicated virus-hTERTC27 (rAAV-hTERTC27) were prepared as previously described [30], and the recombinant viruses were kept at −80°C prior to use.

Subcutaneous tumor inoculation

Melanoma B16 cells were harvested in exponential growth phase by trypsinization and washed twice with ice-cold PBS, and then resuspended into ice-cold PBS at a concentration of 2×106 cells/ml. C57BL/6 mice were subcutaneously injected with B16 cells (2×105 cells/mouse) on the right back flank. 7 days later, each mouse with tumor about 0.2∼0.4 cm3 received a viral cocktail injection (1.5×1011 vg of rAAV-hTERTC27 plus 2.5×109 pfu of rAdv-hTERTC27 for treatment groups; or 1.5×1011 vg of rAAV-EGFP plus 2.5×109 pfu of rAdv-EGFP for viral cocktail control group) or equal volume of PBS injection (for control group) by routes as indicated. Tumor size was measured with calipers every other day. Tumor volume (V) was calculated by the formula, V = 1/2×S×S×L, where S and L are the shortest and longest diameter of the tumor, respectively. Mice were sacrificed on day 21 post-tumor cell injection.

Profile study of lymphocytes in blood by flow cytometry

Peripheral blood was collected from each mouse at sacrifice and mixed with anticoagulant immediately. Plasma was collected by centrifugation at 300 ×g for 5 min, and the cell pellet was washed twice with PBS and resuspended in 0.4 ml of PBS-FBS (PBS, pH 7.4, containing 1% FBS and 0.1% sodium azide). The cell suspension was divided into two parts with equal volume. One part was labeled with PE-conjugated rat anti-mouse CD4 monoclonal antibody and FITC-conjugated rat anti-mouse CD8 monoclonal antibody, while the other part was labeled with PE-conjugated rat anti-mouse CD49b/pan-NK monoclonal antibody and FITC-conjugated rat anti-mouse CD19 monoclonal antibody, for 40 min on ice. For detection of NKT cells, plasma was labeled with PE-conjugated rat anti-mouse CD49b monoclonal antibody and FITC-conjugated rat anti-mouse CD3 monoclonal antibody. After red blood cell lyses and washing, the cells were analyzed by Epics Altra (Bechman Coulter, Miami, FL) and free software WinMDI version 2.8 (http://facs.scripps.edu/software.html).

Depletion of NK cell population in mice

To deplete NK cell population, mice were administered 20 µl of anti-asialo GM1 (Wako Pure Chemical Industries) by intraperitoneal injection 3 days before viral cocktail treatment, followed by repeated injection every five days for duration of two weeks. NK cell population in blood was then analyzed by flow cytometry.

Measurement of cytokine levels

Cytokine levels in plasma collected from mouse peripheral blood were analyzed using TH1/TH2 10plex kit and FlowCytomix Pro 1.0 Software (Bender MedSystems, USA) according to the manufacturer's instructions.

Lymphocyte proliferation activity

Lymphocytes were isolated from splenocytes by HistoPaque-1083 centrifugation and then seeded into 96-well plate with 100 µl per well at the concentration of 5×106 cells/ml. After 72 hrs stimulation with 10 µg/ml ConA or 10 µg/ml LPS, the lymphocyte proliferation activity was analyzed using CellTiter 96 Non-Radioactive Cell Proliferation Assay Kit and the activity of LDH was measured by a spectrophotometer at 490 nm. The stimulation index (SI) was calculated as the formula SI  =  (Mitogen treatment-Background)/(Control-Background).

Cytotoxic activities of NK and CTL

The cytolytic activities of NK and CTL were determined by CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit. Briefly, for NK cytotoxic activity, lymphocytes isolated from spleen of each mouse were incubated with YAC-1 or B16 cells at different effector/target (E:T) ratios at 37°C for 4 hrs, and targeted cell lysis was calculated according to the manufacturer's instructions. For CTL activity, lymphocytes isolated from spleen of each mouse were stimulated with mitomycin C-treated B16 cells (a 2∶1 ratio of lymphocytes and B16) and recombinant mouse IL-2 (mIL-2, 50 ng/ml) in complete culture medium for six days. Culture medium (half of volume) was replenished with fresh medium containing mIL-2 every 3 days. Viable lymphocytes were separated by Histopaque-1083 density gradient centrifugation and then incubated with B16 cells at the indicated E:T ratio at 37°C for 4 hrs. Cytotoxicity was measured using CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit.

Statistical analysis

Student's t test was used to compare tumor volumes and cytotoxicity between experimental groups. Prism 3.0 (GraphPad Software, San Diego California, USA) was used for all calculations, with a P<0.05 deemed statistically significant.

Results

rAAV-/rAdv-hTERTC27 viral cocktail is more effective than either virus alone in suppressing the growth of B16 melanoma in C57BL/6 mice

We first tested the efficacy of the rAAV-/rAdv-hTERTC27 viral cocktail in a melanoma cancer model. C57BL/6 mice received subcutaneous injection of PBS, rAAV-/rAdv-hTERTC27 viral cocktail or either virus alone near the tumors on the 7th day after tumor cell inoculation. As expected, tumors in control mice treated with PBS grew much more rapidly than those in mice treated with either rAAV-hTERTC27 or rAdv-hTERTC27 or both over the observation period (Fig. 1A). Moreover, administration of rAAV-/rAdv-hTERTC27 viral cocktail significantly suppressed tumor growth compared with either virus alone (Fig. 1A).

[Figure omitted. See PDF.]

Figure 1. rAAV-/rAdv-hTERTC27 treatment suppresses the growth of B16 melanoma in C57BL/6 mice.

(A) Anti-tumor efficacy of rAAV-hTERTC27, rAdv-hTERTC27 and rAAV-/rAdv-hTERTC27. Tumor-bearing mice (5mice/group) were subcutaneously injected with viruses as indicated. Tumor growth was monitored by measuring tumor size with calipers every other day till the day when mice sacrificed. *: P<0.05, compared with PBS treated group. (B) Antitumor efficacies of different administration routes of rAAV-/rAdv-hTERTC27 viral cocktail. Tumor-bearing mice were treated by injection of rAAV-/rAdv-hTERTC27, rAAV-/rAdv-EGFP, or PBS as indicated routes, i.e. intratumor (i.t.), intra-muscular (i.m.), intraperitoneal (i.p.), intravenous (i.v.) and subcutaneous (s.c.) injection (3mice/group). *: P<0.05, compared with PBS treated group. (C) Antitumor efficacy of subcutaneous administration of hTERTC27. Melanoma-bearing mice were subcutaneously received rAAV-/rAdv-hTERTC27 viral cocktail (5 mice), rAAV-/rAdv-EGFP viral cocktail (4 mice) or PBS (3 mice) around tumor on 7th day after tumor cell injection, and were sacrificed on day 20 post-tumor cell injection. *: P<0.05, compared with PBS group.

https://doi.org/10.1371/journal.pone.0012705.g001

We then investigated the efficacy of administration routes of rAAV-/rAdv-hTERTC27 in melanoma growth. Mice bearing B16 melanoma were given a single dose of rAAV-/rAdv-hTERTC27 by different routes (intratumoral, intramuscular, intravenous, intraperitoneal, and subcutaneous) or rAAV-/rAdv-EGFP (intratumoral injection), or PBS (intratumoral injection). Tumor growth in mice received intraperitoneal or intramuscular injection of rAAV-/rAdv-hTERTC27 viral cocktail was not significantly different from the control group mice, which received an intratumoral injection with either PBS or rAAV-/rAdv-EGFP viral cocktail (Fig. 1B). However, we observed much slower tumor growth in mice that received intratumoral, intravenous or subcutaneous injection of rAAV-/rAdv-hTERTC27 viral cocktail compared with mice from control groups (Fig. 1B). Unexpectedly, subcutaneous injection of rAAV-/rAdv-hTERTC27 viral cocktail around tumor resulted in the most significant tumor-growth inhibition (Fig. 1B). Consistent results were obtained from another experiment in which mice were injected subcutaneously with rAAV-/rAdv-hTERTC27, rAAV-/rAdv-EGFP or PBS. Again, mice that received rAAV-/rAdv-hTERTC27 exhibited greater tumor growth inhibition than those given rAAV-/rAdv-EGFP or PBS (Fig. 1C).

NK cells population and cytotoxicity are enhanced by administration of rAAV-/rAdv-hTERTC27 viral cocktail

Our previous study indicated that in addition to apoptosis genes, rAAV-hTERTC27 also regulates the expression of genes that are important to immune functions [27]. To test the hypothesis that an immune response is one of the major mechanisms responsible for tumor suppression executed by rAAV-/rAdv-hTERTC27, we analyzed the population profiles of peripheral blood leukocytes by flow cytometry. The population of NK cells was significantly increased in mice treated by rAAV-/rAdv-hTERTC27 viral cocktail (43.4%) compared with mice treated by rAAV-/rAdv-EGFP (12.2%) or PBS (17.7%) (Fig. 2A and 2C). However, there was no significant difference in the populations of B cells, CD4+ T cells and CD8+ T cells between the different treatment groups (Fig. 2B and 2C). The antibody used for pan NK cell (NK1.1+) profile study is an anti-CD49b antibody (DX5) which also recognizes NKT (NK1.1+/CD3+) cells. To clarify whether the population of NKT cells is increased by the rAAV-/rAdv-hTERTC27 treatment, another flow cytometry analysis was performed using PE-conjugated rat anti-mouse CD49b and FITC-conjugated rat anti-mouse CD3 antibodies. As shown in Figure 2F, the population of NK (NK1.1+/CD3−) cells was consistently increased by hTERTC27 treatment. In addition, hTERTC27 increased the population of NKT (NK1.1+/CD3+) cells but did not significantly change the population of NK1.1−/CD3+ T cells (Fig 2F). Although the populations of both NK (NK1.1+/CD3−) cells and NKT (NK1.1+/CD3+) cells were significantly increased by hTERTC27, the increase in NK cell population (192%) is higher than NKT cell population (159%). Moreover, the percentage of NK cells (30%) in PMBC is much higher than that of NKT cells (6%) (Fig 2F). These results suggest that NK (NK1.1+/CD3−) cells may play much more important roles than NKT cells (NK1.1+/CD3+) in suppressing xenografted tumor growth.

[Figure omitted. See PDF.]

Figure 2. rAAV-/rAdv-hTERTC27 treatment increases the population and cytotoxicity of NK cells.

(A) & (B) Flow cytometric analysis of PMBC from tumor-bearing mice treated with subcutaneous administration of rAAV-/rAdv-hTERTC27, rAAV-/rAdv-EGFP, or PBS. Data shown here represent one of several mice analyzed with similar results. (C) Lymphocyte profiles from A & B (data pooled from 3 mice/group treated with indicated viruses or PBS). *P<0.05, compared with EGFP group. (D) and (E): Cytotoxic activity of spleen NK cells isolated from mice treated with rAAV-/rAdv-hTERTC27, rAAV-/rAdv-EGFP or PBS was analyzed against YAC-1 (D) or B16 (E) cells. Lymphocytes isolated from each mouse were cultured with YAC-1 or B16 cells at various effector to target ratios (E/T). *: P<0.05, compared with EGFP group. (F): Profiles of NKT (NK1.1+/CD3+), NK (NK1.1+/CD3−) and T (NK1.1−/CD3+) cells in PMBC from tumor-bearing mice treated with rAAV-/rAdv-hTERTC27 or rAAV-/rAdv-EGFP. The numerical value presented with the bar graph indicates the percentage of the cell population in PMBC. The cell population without any marker (i.e. NK1.1−/CD3−) is not shown. Data pooled from 3 mice/group treated with indicated virus through flow cytometry analysis. *: P<0.05, compared with EGFP group.

https://doi.org/10.1371/journal.pone.0012705.g002

To further investigate whether administration of rAAV-/rAdv-hTERTC27 viral cocktail can increase the cytolytic activity of NK cells, NK cell cytotoxicity assay was performed. Lymphocytes from mice that received rAAV-/rAdv-hTERTC27 injection exhibited a significant increase in YAC-1 (a target cell of NK) killing activity as compared to those from mice treated with rAAV-/rAdv-EGFP or PBS at the E/T ratios of 50∶1 and 12.5∶1, respectively (Fig. 2D). In addition, lymphocytes from mice treated with rAAV-/rAdv-hTERTC27 also exhibited higher cytotoxicity to B16 cells than those from mice treated with rAAV-/rAdv-EGFP or PBS at the E/T ratio of 50∶1 (Fig. 2E).

Suppression of NK cell impairs the antitumor effects of rAAV-/rAdv-hTERTC27 administration

The remarkable increase in the population and cytotoxicity of NK cells in hTERTC27 treated mice strongly hinted that NK cell is crucial for hTERTC27-induced tumor suppression. To test this hypothesis, NK cell population was depleted in mice by intraperitoneal injection of anti-GM1 antibody, and its effect on tumor growth during the rAAV-/rAdv-hTERTC27 treatment was investigated. As shown in Figure 3A, injection of anti-GM1 antibody specifically reduced NK cell population in PBMC, whereas helper T cells (CD4+), cytotoxic T cells (CD8+), B cells (CD19+) (Fig. 3B), and regulatory T cells were unaffected (Fig. 3D). Consistently, the cytotoxicity of splenocytes to YAC-1 was decreased in anti-GM1 antibody-treated mice (Fig. 3C). Strikingly, anti-GM1 antibody injection completely abolished the tumor growth suppression induced by hTERTC27 treatment (Fig. 3E, 3F). Taken together, the results suggest that NK cell activation is crucial for the anti-tumor effect of hTERTC27.

[Figure omitted. See PDF.]

Figure 3. NK cell activity is crucial for the anti-tumor effect of hTERTC27.

PMBC from mice intraperitoneally injected with anti-GM1 antibody were analyzed for populations of NK cells (A), helper T cell/cytotoxic T cell/B cell (B) and regulatory T cell (D) by flow cytometry. (C) Cytotoxicity of NK cells against YAC-1. Lymphocytes isolated from spleen of each mouse were cultured with YAC-1 cells at various E/T ratios, and the specific lysis was determined using CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit. (E) NK cell depletion abrogated the anti-tumor effects of rAAV-/rAdv-hTERTC27 in C57BL/6 mice. *: P<0.05, compared with EGFP group. (F) A representative photo of tumor morphology from different treatment groups. hTERTC27: hTERTC27 viral cocktail; EGFP: EGFP viral cocktail. *: P<0.05, compared with hTERTC27 group.

https://doi.org/10.1371/journal.pone.0012705.g003

TH1 cytokine secretion is increased after administration of rAAV-/rAdv-hTERTC27

To investigate blood cytokine levels, plasma from mice treated with rAAV-/rAdv-hTERTC27 and rAAV-/rAdv-EGFP viral cocktails was collected and analyzed using Mouse Th1/Th2 FlowCytomix kit. TH1 and TH2 cytokines refer to the patterns of cytokines secreted by two different subpopulations of CD4+ T cells that determine the outcome of an antigenic response toward humoral and cell-mediated immunity, respectively. Th1 cytokines include IL-2, IFN-γ, IL-12 and TNF-β, and Th2 cytokines include IL-4, IL-5, IL-6, IL-10 and IL-13. The levels of mIL-2, mIFN-γ, and mGM-CSF in blood of mice treated with hTERTC27 were 3.3-, 185- and 3.9-fold, respectively, higher than those in the blood of mice treated with EGFP. We did not observe a significant change in the level of other cytokines (e.g. IL-4, IL-5, IL-6, IL-10 and IL-17) between hTERTC27-treated mice and EGFP-treated mice (the level difference is <2-fold) (Fig.4).

[Figure omitted. See PDF.]

Figure 4. rAAV-/rAdv-hTERTC27 treatment increases plasma levels of Th1 cytokines.

Plasma from sacrificed mice on day 20 post tumor cell inoculation were analyzed to determine cytokine levels using mouse Th1/Th2 FlowCytomix assay kit. The numerical values presented with the bar graph indicate the fold differences of cytokine levels between mice treated with hTERTC27 and EGFP.

https://doi.org/10.1371/journal.pone.0012705.g004

T cell activity is enhanced by administration of rAAV-/rAdv-hTERTC27

Lymphocytes from spleen were treated with ConA (10 µg/ml) or LPS (10 µg/ml) to investigate whether administration of hTERTC27 viral cocktail can increase the proliferation activity of T cells or B cells. As shown in Figure 5A, there is no significant difference in B cell proliferation activity among groups treated with rAAV-/rAdv-hTERTC27, rAAV-/rAdv-EGFP or PBS. However, a slight but significant increase in T cell proliferation was observed in mice treated with rAAV-/rAdv-hTERTC27 as opposed to those treated with rAAV-/rAdv-EGFP or PBS. Consistent with the T cell proliferation assay, the cytotoxicity of spleen T lymphocytes was a little higher in mice treated with rAAV-/rAdv-hTERTC27 than in those treated with rAAV-/rAdv-EGFP or PBS (Fig. 5B).

[Figure omitted. See PDF.]

Figure 5. rAAV-/rAdv-hTERTC27 treatment has different effects on the activities of T cells and B cells.

(A) Proliferation activity of T cells and B cells isolated from mice treated with hTERTC27, EGFP or PBS. Data are expressed as means ± SD (n = 3). *: P<0.05, compared with EGFP group. (B) Cytotoxicity of T cells isolated from mice treated with hTERTC27, EGFP, or PBS. *: P<0.05, compared with EGFP group.

https://doi.org/10.1371/journal.pone.0012705.g005

Discussion

In this study, we demonstrated for the first time that rAAV-/rAdv-hTERTC27, a viral cancer therapy effective in treating glioblastoma [30], also provides therapeutic benefit against murine melanoma. Our data suggest that rAAV-/rAdv-hTERTC27 acts through enhancing anti-tumor innate immunity.

The rationale of combining rAAV with rAdv vectors is that a non-therapeutic dose of rAdv-null can greatly increase the transduction level of rAAV, and a combination of therapeutic dose of rAdv-Luc (2.5×109 pfu) and rAAV-Luc (1.5×1011 v.g.) dramatically increased the luciferase expression level in vivo [29], [30]. Therefore, a better beneficial antitumor effect was achieved by combining rAAV-hTERTC27 with rAdv-hTERTC27 compared with either one alone, suggesting that the enhanced expression level of hTERTC27 likely played a role.

As a universal tumor-associated antigen, TERT is an ideal target for cancer therapy. Conceptually, three approaches have exploited TERT for cancer therapy: gene therapy (using viral gene transfer to interfere telomerase activity or express suicide gene under TERT promoter), immunotherapy (stimulating TERT-specific immune response to kill TERT-expressing cells), and small-molecule inhibitors (using peptide/chemical drugs to inhibit telomerase activity) [31]. Previously, rAAV-hTERTC27 was developed as a TERT-targeting gene therapy [27]. Here, investigation of the mechanism by which rAAV-/rAdv-hTERTC27 inhibits melanoma led us to believe that one of the effects of rAAV-/rAdv-hTERTC27 might be the enhanced cancer immunosurveillance mediated mainly by NK cells since 1) a single dose administration of rAAV-/rAdv-hTERTC27 not only increased the population of blood NK cells by about two fold (Fig. 2) but also enhanced the specific cytotoxicity of splenic NK cells to YAC-1 and B16 cells (Fig. 5); 2) selective depletion of NK cells which are known to play important roles in tumor immunosurveillance in vivo [32] but not NKT cells by the anti-GM1 antibody [33]–[36] completely abrogated the antitumor effects of hTERTC27 (Fig. 3E). Although the population of NKT cells in PMBC was also increased by rAAV-/rAdv-hTERTC27 (Fig. 2F), the percentage of the NKT cells (6%) was too low as compared to that of NK cells (30%) to be the major effector cells which can induce such significant tumor growth suppression.

Our study indicates that activation of NK cells by hTERTC27 is sufficient to inhibit melanoma growth in mouse model, pinpointing the importance of NK cell activation in cancer immunotherapy. These observations are consistent with our previous study that rAAV-hTERTC27 administration effectively inhibited glioblastoma growth in nude mice, where T cells are absent but NK cells are functional. Consistently, a previous study also indicated that activation of NK cells can provide effective innate immunotherapy of melanoma in mouse model [37].

The NK activity-stimulating effect of rAAV-/rAdv-hTERTC27 represents a novel way to exploit the functions of TERT in cancer treatment. hTERTC27 contains two peptides, p973 and p988, both of which have been shown to induce TERT specific CTLs in vitro or in vivo to lyse TERT+ tumor cells, including melanoma B16 cells [38], [39]. It has also been reported that dendritic cells (DCs) pulsed with peptide p540 can elicit CTLs ex vivo to lyse hTERT+ tumor cells, including human melanoma cells K029 [25]. DCs transfected with mTERT gene can also induce CTLs to lyse B16 cells and inhibit B16 melanoma metastasis [40]. Apparently, the mechanism of hTERTC27-induced tumor suppression in our study is different from that of peptides (p973, p988, p540) or TERT gene transfected DCs reported in other studies. hTERTC27 may contain other unknown epitopes that have a tendency to induce a strong innate immune response other than an adaptive immune response. Not surprisingly, a single-peptide epitope (e.g. p988 or p973) tends to induce adaptive immunity because such single peptide is screened by CTL assay [38], [39]. In fact, some other epitopes which induce activation of CD4+ T cells but not CD8+ T cells from hTERT have been identified [41], [42], suggesting that some epitopes that specifically induce other immune cells may also exist. Thus, further study to identify the epitopes of hTERTC27 will likely be crucial to dissect the mechanism of hTERTC27-induced NK cell activation in vivo.

rAAV-/rAdv-hTERTC27 significantly inhibited B16 tumor growth when administered by intravenous, intratumor and subcutaneous injection. However, subcutaneous injection of rAAV-/rAdv-hTERTC27 viral cocktail near tumor site produced the most significant antitumor effect. Although it is unclear what might have contributed to the differences of antitumor effect among these administration routes, it has been reported that the induction of immunity (humoral, cell-mediated, or both) against the transgene product carried by rAAV depends on the routes of administration [43]. Therefore, intratumoral, intravenous or subcutaneous administration of rAAV-/rAdv-hTERTC27 may preferentially enable the stimulation of innate anti-tumor immunity. It will be interesting to investigate the effect of different administration routes on NK cell population and activation. Our observation implies that careful selection of administration route may be important for cancer gene therapy.

The population of T cells (CD4+ and CD8+) and B cells in blood did not vary significantly between the mice treated with rAAV-/rAdv-hTERTC27 and those treated with rAAV-/rAdv-EGFP or PBS (Fig. 2). Although small differences in T cell proliferation activity and CTL cytotoxicity were observed between hTERTC27 treated mice and control group mice (Fig. 5), they were mild and unlikely to be the major determinants responsible for the significant tumor suppression induced by rAAV-/rAdv-hTERTC27 observed in our study. A minor increase of CTL cytotoxicity in spleen lymphocytes might be a result of increased levels of Th1 cytokine in blood. A considerable increase in the levels of IL-2, IFN-γ and GM-CSF was observed in the plasma of mice treated with rAAV-/rAdv-hTERTC27 compared with the control mice (Fig. 4). All these cytokines function as an immune adjuvant and are known to contribute to the development and activity of tumor specific CTL [40], [42], [44]. However, further investigation is required to determine whether cytokines such as IL-2 and IFN-γ could increase the population of cytokine-induced-killer cells (CIK) [45] in vivo and contribute to the antitumor effects of hTERTC27. Unlike our previous study in which ectopic expression of rAAV-hTERTC27 in nude mice significantly up-regulated the IL-17 mRNA level [27] in xenografted tumor tissue, administration of rAAV-/rAdv-hTERTC27 viral cocktail in C57BL/6 mice showed a little increase of IL-17 cytokine level in blood in this study. The discrepancy may come from the different mouse models and delivery systems used between these two studies. Nonetheless, the slight change in IL-17 level is consistent with the mild increase in activated T cells because it is known that IL-17 expression is restricted to activated T-cells [46].

It is worth noting that NK cells are known to play a major role in cytokine-mediated inhibition of B16 melanoma development [47]–[51] and that IL-2 can induce the proliferation and activity of NK cells [48], [52]–[54]. Moreover, activated NK cells can secrete several cytokines, including IFN-γ and GM-CSF [55] and increase IL-2 mRNA expression [56]. In addition, IFN-γ itself also activates NK cells [57]. Because of the complex relationship between NK cells and these cytokines, the initial effect following hTERTC27 administration remains elusive and requires further investigation.

Acknowledgments

We thank Dr. Jennifer L. Hsu for proofreading this manuscript.

Author Contributions

Conceived and designed the experiments: LH. Performed the experiments: LH HY GWW. Analyzed the data: LH HY XW GWW HFK. Contributed reagents/materials/analysis tools: LH XW HFK. Wrote the paper: LH.

Citation: Huo L, Yao H, Wang X, Wong GW, Kung H-f, Lin MC (2010) Inhibition of Melanoma Growth by Subcutaneous Administration of hTERTC27 Viral Cocktail in C57BL/6 Mice. PLoS ONE5(9): e12705. https://doi.org/10.1371/journal.pone.0012705

References

1. Thompson JF, Scolyer RA, Kefford RF (2009) Cutaneous melanoma in the era of molecular profiling. Lancet 374: 362–365.JF ThompsonRA ScolyerRF Kefford2009Cutaneous melanoma in the era of molecular profiling.Lancet374362365

2. Pawlik TM, Sondak VK (2003) Malignant melanoma: current state of primary and adjuvant treatment. Crit Rev Oncol Hematol 45: 245–264.TM PawlikVK Sondak2003Malignant melanoma: current state of primary and adjuvant treatment.Crit Rev Oncol Hematol45245264

3. Eggermont AM, Kirkwood JM (2004) Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 40: 1825–1836.AM EggermontJM Kirkwood2004Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?Eur J Cancer4018251836

4. Brown CK, Kirkwood JM (2003) Medical management of melanoma. Surg Clin North Am 83: 283–322, viii.CK BrownJM Kirkwood2003Medical management of melanoma.Surg Clin North Am83283322, viii

5. Flaherty LE, Atkins M, Sosman J, Weiss G, Clark JI, et al. (2001) Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J Clin Oncol 19: 3194–3202.LE FlahertyM. AtkinsJ. SosmanG. WeissJI Clark2001Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.J Clin Oncol1931943202

6. Huncharek M, Caubet JF, McGarry R (2001) Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 11: 75–81.M. HuncharekJF CaubetR. McGarry2001Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.Melanoma Res117581

7. Tarhini AA, Agarwala SS (2006) Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 19: 19–25.AA TarhiniSS Agarwala2006Cutaneous melanoma: available therapy for metastatic disease.Dermatol Ther191925

8. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351: 998–1012.H. TsaoMB AtkinsAJ Sober2004Management of cutaneous melanoma.N Engl J Med3519981012

9. Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 23: 488–496.S. BhatiaSS TykodiJA Thompson2009Treatment of metastatic melanoma: an overview.Oncology (Williston Park)23488496

10. Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, et al. (2009) Immunotherapy of distant metastatic disease. Ann Oncol 20: Suppl 6vi41–50.D. SchadendorfSM AlgarraL. BastholtG. CinatB. Dreno2009Immunotherapy of distant metastatic disease.Ann Oncol20Suppl 6vi4150

11. Queirolo P, Acquati M (2005) Biochemotherapy in metastatic melanoma: quo vadis? Melanoma Res 15: 471–473.P. QueiroloM. Acquati2005Biochemotherapy in metastatic melanoma: quo vadis?Melanoma Res15471473

12. Lens M, Ferrucci PF, Testori A (2008) Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings. Recent Pat Anticancer Drug Discov 3: 105–113.M. LensPF FerrucciA. Testori2008Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.Recent Pat Anticancer Drug Discov3105113

13. Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, et al. (2009) Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 218: 69–70.A. EckertA. SchoefflerS. DalleA. PhanL. Kiakouama2009Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient.Dermatology2186970

14. Fadel F, El Karoui K, Knebelmann B (2009) Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361: 211–212.F. FadelK. El KarouiB. Knebelmann2009Anti-CTLA4 antibody-induced lupus nephritis.N Engl J Med361211212

15. Blesa JMG, Pulido EG, Pulla MP, Candel VA (2009) Treatment options for metastatic melanoma-A systematic review. Cancer Therapy 7: 188–199.JMG BlesaEG PulidoMP PullaVA Candel2009Treatment options for metastatic melanoma-A systematic review.Cancer Therapy7188199

16. Pilla L, Rivoltini L, Patuzzo R, Marrari A, Valdagni R, et al. (2009) Multipeptide vaccination in cancer patients. Expert Opin Biol Ther 9: 1043–1055.L. PillaL. RivoltiniR. PatuzzoA. MarrariR. Valdagni2009Multipeptide vaccination in cancer patients.Expert Opin Biol Ther910431055

17. Pilla L, Valenti R, Marrari A, Patuzzo R, Santinami M, et al. (2006) Vaccination: role in metastatic melanoma. Expert Rev Anticancer Ther 6: 1305–1318.L. PillaR. ValentiA. MarrariR. PatuzzoM. Santinami2006Vaccination: role in metastatic melanoma.Expert Rev Anticancer Ther613051318

18. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909–915.SA RosenbergJC YangNP Restifo2004Cancer immunotherapy: moving beyond current vaccines.Nat Med10909915

19. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, et al. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011–2015.NW KimMA PiatyszekKR ProwseCB HarleyMD West1994Specific association of human telomerase activity with immortal cells and cancer.Science26620112015

20. Zimmermann S, Martens UM (2007) Telomeres and telomerase as targets for cancer therapy. Cell Mol Life Sci 64: 906–921.S. ZimmermannUM Martens2007Telomeres and telomerase as targets for cancer therapy.Cell Mol Life Sci64906921

21. Kim NW (1997) Clinical implications of telomerase in cancer. Eur J Cancer 33: 781–786.NW Kim1997Clinical implications of telomerase in cancer.Eur J Cancer33781786

22. Ramakrishnan S, Eppenberger U, Mueller H, Shinkai Y, Narayanan R (1998) Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res 58: 622–625.S. RamakrishnanU. EppenbergerH. MuellerY. ShinkaiR. Narayanan1998Expression profile of the putative catalytic subunit of the telomerase gene.Cancer Res58622625

23. Huo LF, Tang JW, Huang JJ, Huang PT, Huang CF, et al. (2006) Cancer immunotherapy targeting the telomerase reverse transcriptase. Cell Mol Immunol 3: 1–11.LF HuoJW TangJJ HuangPT HuangCF Huang2006Cancer immunotherapy targeting the telomerase reverse transcriptase.Cell Mol Immunol3111

24. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, et al. (2000) Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A 97: 4796–4801.B. MinevJ. HippH. FiratJD SchmidtP. Langlade-Demoyen2000Cytotoxic T cell immunity against telomerase reverse transcriptase in humans.Proc Natl Acad Sci U S A9747964801

25. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10: 673–679.RH VonderheideWC HahnJL SchultzeLM Nadler1999The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes.Immunity10673679

26. Huang JJ, Lin MC, Bai YX, Jing DD, Wong BC, et al. (2002) Ectopic expression of a COOH-terminal fragment of the human telomerase reverse transcriptase leads to telomere dysfunction and reduction of growth and tumorigenicity in HeLa cells. Cancer Res 62: 3226–3232.JJ HuangMC LinYX BaiDD JingBC Wong2002Ectopic expression of a COOH-terminal fragment of the human telomerase reverse transcriptase leads to telomere dysfunction and reduction of growth and tumorigenicity in HeLa cells.Cancer Res6232263232

27. Ng SS, Gao Y, Chau DH, Li GH, Lai LH, et al. (2007) A novel glioblastoma cancer gene therapy using AAV-mediated long-term expression of human TERT C-terminal polypeptide. Cancer Gene Ther 14: 561–572.SS NgY. GaoDH ChauGH LiLH Lai2007A novel glioblastoma cancer gene therapy using AAV-mediated long-term expression of human TERT C-terminal polypeptide.Cancer Gene Ther14561572

28. Ferrari FK, Samulski T, Shenk T, Samulski RJ (1996) Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 70: 3227–3234.FK FerrariT. SamulskiT. ShenkRJ Samulski1996Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors.J Virol7032273234

29. Chen Y, Luk KD, Cheung KM, Lu WW, An XM, et al. (2004) Combination of adeno-associated virus and adenovirus vectors expressing bone morphogenetic protein-2 produces enhanced osteogenic activity in immunocompetent rats. Biochem Biophys Res Commun 317: 675–681.Y. ChenKD LukKM CheungWW LuXM An2004Combination of adeno-associated virus and adenovirus vectors expressing bone morphogenetic protein-2 produces enhanced osteogenic activity in immunocompetent rats.Biochem Biophys Res Commun317675681

30. Gao Y, Ng SS, Chau DH, Yao H, Yang C, et al. (2008) Development of recombinant adeno-associated virus and adenovirus cocktail system for efficient hTERTC27 polypeptide-mediated cancer gene therapy. Cancer Gene Ther 15: 723–732.Y. GaoSS NgDH ChauH. YaoC. Yang2008Development of recombinant adeno-associated virus and adenovirus cocktail system for efficient hTERTC27 polypeptide-mediated cancer gene therapy.Cancer Gene Ther15723732

31. Shay JW, Keith WN (2008) Targeting telomerase for cancer therapeutics. Br J Cancer 98: 677–683.JW ShayWN Keith2008Targeting telomerase for cancer therapeutics.Br J Cancer98677683

32. Waldhauer I, Steinle A (2008) NK cells and cancer immunosurveillance. Oncogene 27: 5932–5943.I. WaldhauerA. Steinle2008NK cells and cancer immunosurveillance.Oncogene2759325943

33. Duthie MS, Kahn SJ (2006) During acute Trypanosoma cruzi infection highly susceptible mice deficient in natural killer cells are protected by a single alpha-galactosylceramide treatment. Immunology 119: 355–361.MS DuthieSJ Kahn2006During acute Trypanosoma cruzi infection highly susceptible mice deficient in natural killer cells are protected by a single alpha-galactosylceramide treatment.Immunology119355361

34. Rottenberg M, Cardoni RL, Andersson R, Segura EL, Orn A (1988) Role of T helper/inducer cells as well as natural killer cells in resistance to Trypanosoma cruzi infection. Scand J Immunol 28: 573–582.M. RottenbergRL CardoniR. AnderssonEL SeguraA. Orn1988Role of T helper/inducer cells as well as natural killer cells in resistance to Trypanosoma cruzi infection.Scand J Immunol28573582

35. Ishikawa H, Hisaeda H, Taniguchi M, Nakayama T, Sakai T, et al. (2000) CD4(+) v(alpha)14 NKT cells play a crucial role in an early stage of protective immunity against infection with Leishmania major. Int Immunol 12: 1267–1274.H. IshikawaH. HisaedaM. TaniguchiT. NakayamaT. Sakai2000CD4(+) v(alpha)14 NKT cells play a crucial role in an early stage of protective immunity against infection with Leishmania major.Int Immunol1212671274

36. Sun R, Tian Z, Kulkarni S, Gao B (2004) IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4+ T cell- and STAT3-dependent manners. J Immunol 172: 5648–5655.R. SunZ. TianS. KulkarniB. Gao2004IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4+ T cell- and STAT3-dependent manners.J Immunol17256485655

37. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, et al. (2005) Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med 201: 1973–1985.MJ SmythME WallaceSL NuttH. YagitaDI Godfrey2005Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer.J Exp Med20119731985

38. Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, et al. (2002) HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168: 5900–5906.A. ScardinoDA GrossP. AlvesJL SchultzeS. Graff-Dubois2002HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy.J Immunol16859005906

39. Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, et al. (2001) Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 7: 3343–3348.RH VonderheideKS AndersonWC HahnMO ButlerJL Schultze2001Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.Clin Cancer Res733433348

40. Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, et al. (2000) Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6: 1011–1017.SK NairA. HeiserD. BoczkowskiA. MajumdarM. Naoe2000Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.Nat Med610111017

41. Schroers R, Huang XF, Hammer J, Zhang J, Chen SY (2002) Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res 62: 2600–2605.R. SchroersXF HuangJ. HammerJ. ZhangSY Chen2002Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells.Cancer Res6226002605

42. Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, et al. (2003) Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 9: 4743–4755.R. SchroersL. ShenL. RollinsCM RooneyK. Slawin2003Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes.Clin Cancer Res947434755

43. Brockstedt DG, Podsakoff GM, Fong L, Kurtzman G, Mueller-Ruchholtz W, et al. (1999) Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol 92: 67–75.DG BrockstedtGM PodsakoffL. FongG. KurtzmanW. Mueller-Ruchholtz1999Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration.Clin Immunol926775

44. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, et al. (2003) Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102: 964–971.S. NairD. BoczkowskiB. MoellerM. DewhirstJ. Vieweg2003Synergy between tumor immunotherapy and antiangiogenic therapy.Blood102964971

45. Linn YC, Hui KM (2003) Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk Lymphoma 44: 1457–1462.YC LinnKM Hui2003Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.Leuk Lymphoma4414571462

46. Aggarwal S, Gurney AL (2002) IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 71: 1–8.S. AggarwalAL Gurney2002IL-17: prototype member of an emerging cytokine family.J Leukoc Biol7118

47. Kijima M, Saio M, Oyang GF, Suwa T, Miyauchi R, et al. (2005) Natural killer cells play a role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro. Int J Oncol 26: 679–684.M. KijimaM. SaioGF OyangT. SuwaR. Miyauchi2005Natural killer cells play a role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro.Int J Oncol26679684

48. Misawa E, Sakurai T, Yamada M, Hayasawa H, Motoyoshi K (2003) Booster effect of interleukin-2 on natural killer 1.1+ cells stimulated by administration of macrophage colony-stimulating factor in mice. J Immunother 26: 21–30.E. MisawaT. SakuraiM. YamadaH. HayasawaK. Motoyoshi2003Booster effect of interleukin-2 on natural killer 1.1+ cells stimulated by administration of macrophage colony-stimulating factor in mice.J Immunother262130

49. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T (2006) Antitumor activity of IFN-lambda in murine tumor models. J Immunol 176: 7686–7694.A. SatoM. OhtsukiM. HataE. KobayashiT. Murakami2006Antitumor activity of IFN-lambda in murine tumor models.J Immunol17676867694

50. Wang G, Tschoi M, Spolski R, Lou Y, Ozaki K, et al. (2003) In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 63: 9016–9022.G. WangM. TschoiR. SpolskiY. LouK. Ozaki2003In vivo antitumor activity of interleukin 21 mediated by natural killer cells.Cancer Res6390169022

51. Yajima T, Nishimura H, Wajjwalku W, Harada M, Kuwano H, et al. (2002) Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response. Int J Cancer 99: 573–578.T. YajimaH. NishimuraW. WajjwalkuM. HaradaH. Kuwano2002Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response.Int J Cancer99573578

52. Clark PR, Stopeck AT, Parker SE, Hersh EM (2000) Cationic lipid gene transfer of an IL-2 transgene leads to activation of natural killer cells in a SCID mouse human tumor xenograft. Cell Immunol 204: 96–104.PR ClarkAT StopeckSE ParkerEM Hersh2000Cationic lipid gene transfer of an IL-2 transgene leads to activation of natural killer cells in a SCID mouse human tumor xenograft.Cell Immunol20496104

53. Ortaldo JR, Winkler-Pickett RT, Bere EW Jr, Watanabe M, Murphy WJ, et al. (2005) In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells. J Immunol 175: 693–699.JR OrtaldoRT Winkler-PickettEW Bere JrM. WatanabeWJ Murphy2005In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells.J Immunol175693699

54. Talmadge JE, Phillips H, Schindler J, Tribble H, Pennington R (1987) Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res 47: 5725–5732.JE TalmadgeH. PhillipsJ. SchindlerH. TribbleR. Pennington1987Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.Cancer Res4757255732

55. Ye J, Ortaldo JR, Conlon K, Winkler-Pickett R, Young HA (1995) Cellular and molecular mechanisms of IFN-gamma production induced by IL-2 and IL-12 in a human NK cell line. J Leukoc Biol 58: 225–233.J. YeJR OrtaldoK. ConlonR. Winkler-PickettHA Young1995Cellular and molecular mechanisms of IFN-gamma production induced by IL-2 and IL-12 in a human NK cell line.J Leukoc Biol58225233

56. Kurosawa S, Harada M, Matsuzaki G, Shinomiya Y, Terao H, et al. (1995) Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes. Immunology 85: 338–346.S. KurosawaM. HaradaG. MatsuzakiY. ShinomiyaH. Terao1995Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes.Immunology85338346

57. Talmadge JE, Tribble HR, Pennington RW, Phillips H, Wiltrout RH (1987) Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice. Cancer Res 47: 2563–2570.JE TalmadgeHR TribbleRW PenningtonH. PhillipsRH Wiltrout1987Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice.Cancer Res4725632570